Muscle Preservation in Severe/Bedbound - Relevance to ME/CFS

1 Morris et al. 2008 — Early ICU Mobility Therapy

Full Citation:: Morris PE, Goad A, Thompson C, Taylor K, Harry B, Passmore L, Ross A, Anderson L, Baker S, Sanchez M, Penley L, Howard A, Dixon L, Leach S, Small R, Hite RD, Haponik E. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Critical Care Medicine. 2008;36(8):2238–2243. (P. E. Morris et al. 2008) DOI:: 10.1097/CCM.0b013e318180b90e PMID:: 18596631 Published:: August 2008 Study Design:: Prospective cohort study Sample Size:: n=330 (165 protocol, 165 usual care) Key Findings::

- Protocol group: 80% received physical therapy vs. 47% usual care (p ≤ 0.001)
- Earlier mobilization: 5 vs. 11 days to out-of-bed (p ≤ 0.001)
- Reduced ICU LOS: 5.5 vs. 6.9 days (p = 0.025)
- Reduced hospital LOS: 11.2 vs. 14.5 days (p = 0.006)
- Similar low complication rates between groups
- No untoward events during mobility sessions
- No cost difference between arms

Conclusion:: A Mobility Team using a mobility protocol initiated earlier physical therapy that was feasible, safe, did not increase costs, and was associated with decreased ICU and hospital length of stay. Limitations:: Wrong patient population (acute ICU vs. chronic ME/CFS); no assessment of fatigue or post-exertional symptoms; relatively short ICU stay timeframe; protocol includes active mobility beyond pure PROM. ME/CFS Relevance:: Establishes safety and feasibility of early, protocolized PROM and mobility in ventilated ICU patients. Provides precedent for structured positioning protocols in bedbound populations. However, ME/CFS patients differ fundamentally: ICU protocols involve active participation and physiological reserves absent in severe ME/CFS. PEM risk: HIGH if activity intensity or duration exceeds tolerance. Certainty Assessment::

- *Quality:* Medium (Critical Care Medicine; moderate sample size; single study)
- *Certainty:* 0.55
- *Limitation:* ICU population not directly translatable; no PEM assessment

2 Wollersheim et al. 2017 — Whole-Body Vibration with PROM in ICU

Full Citation:: Wollersheim T, Haas K, Wolf S, Mai K, Spies C, Steinhagen-Thiessen E, Wernecke KD, Spranger J, Weber-Carstens S. Whole-body vibration to prevent intensive care unit-acquired weakness: safety, feasibility, and metabolic response. Critical Care. 2017;21(1):9. (Wollersheim et al. 2017) DOI:: 10.1186/s13054-016-1576-y PMID:: 28065165 Published:: January 9, 2017 Study Design:: Clinical trial Sample Size:: n=19 mechanically ventilated ICU patients Key Findings::

- PROM performed prior to WBV therapy (6 minutes)
- WBV applied in supine position for 15 minutes
- Vital signs and hemodynamic parameters remained stable
- No adverse events observed
- No application interruptions required
- Significant increase in energy expenditure during WBV
- Protocol: baseline (10 min rest) → physiotherapy (6 min PROM) → short rest → WBV (15 min) → post-rest

Conclusion:: The application of whole-body vibration was safe and feasible. The technique leads to increased energy expenditure. Limitations:: Small sample size; no control group; short intervention period; no long-term outcomes; no assessment of muscle strength, bone density, or functional outcomes. ME/CFS Relevance:: Demonstrates safety of PROM combined with low-intensity mechanical stimulation (WBV) in immobilized, critically ill patients. The supine positioning and passive nature of initial phase is potentially translatable. However, WBV increased energy expenditure, which is concerning for ME/CFS patients with metabolic dysfunction. PEM risk: MODERATE-HIGH due to increased metabolic demand from WBV component. Certainty Assessment::

- *Quality:* Medium-Low (Critical Care; small sample; safety-focused; no control group)
- *Certainty:* 0.48
- *Limitation:* Increased energy expenditure concerning for ME/CFS

3 Bao et al. 2022 — NMES with PROM Component in ICU

Full Citation:: Bao W, Yang J, Li M, Chen K, Ma Z, Bai Y, Xu Y. Prevention of muscle atrophy in ICU patients without nerve injury by neuromuscular electrical stimulation: a randomized controlled study. BMC Musculoskeletal Disorders. 2022;23(1):780. (Bao et al. 2022) DOI:: 10.1186/s12891-022-05739-2 PMID:: 35974369 Published:: August 16, 2022 Study Design:: Randomized controlled trial (3 arms) Sample Size:: n=? (RCT with 3 arms) Key Findings::

- Groups: Exp I (APAT + NMES gastrocnemius + tibialis anterior), Exp II (APAT + NMES gastrocnemius alone), Control (APAT alone)
- APAT = active and passive activity training (includes PROM)
- All groups showed downward trend in muscle strength, ROM, CSA (atrophy irreversible overall)
- Decrease in gastrocnemius strength smaller in Exp I and II vs. control (p < 0.05)
- Decrease in active ankle ROM smaller in Exp I and II vs. control (p < 0.05)
- Decrease in muscle CSA smaller in Exp I and II vs. control (p < 0.05)
- Exp I (dual-muscle NMES) performed better than Exp II (single-muscle NMES)
- No significant differences in CRP, lactic acid, PT during treatment

Conclusion:: In addition to early exercise training, NMES should be applied to prevent muscle atrophy for patients without nerve injury in ICU. Also, simultaneous NMES treatment on agonist/antagonist muscle can enhance the effect. Limitations:: Sample size not fully specified; ICU population; APAT includes active training not translatable to severe ME/CFS; all groups still experienced muscle loss (only rate reduced); no PEM or fatigue assessment. ME/CFS Relevance:: Incorporates PROM as part of APAT protocol. Demonstrates that combining PROM with low-intensity stimulation (NMES) may mitigate atrophy more effectively than PROM alone. However, APAT includes “active” training component that is likely inappropriate for severe ME/CFS. PEM risk: HIGH if APAT’s active component is used; MODERATE if only PROM + NMES applied cautiously. Certainty Assessment::

- *Quality:* Medium (BMC Musculoskeletal Disorders; RCT; peer-reviewed)
- *Certainty:* 0.52
- *Limitation:* APAT includes active component; sample size not fully specified

4 Deutz et al. 2013 — HMB for Lean Body Mass Preservation During Bed Rest

Full Citation:: Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, Wolfe RR. Effect of {\({\beta}\)}-hydroxy-{\({\beta}\)}-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clinical Nutrition. 2013;32(5):704–712. (Deutz et al. 2013) DOI:: 10.1016/j.clnu.2013.02.011 PMID:: 23514626 Published:: October 2013 Study Design:: Randomized, controlled, double-blinded, parallel-group Sample Size:: n=19 evaluable (Control=8, HMB=11) from n=24 enrolled Key Findings::

- Participants: 20 women, 4 men, age 60-76 years, SPPB ≥ 9 (healthy function at baseline)
- Intervention: HMB (calcium salt) 1.5 g twice daily (3 g/day total)
- Treatment timeline: 5 days pre-bed rest → 10 days complete bed rest → 8 weeks resistance training rehabilitation
- **Control group:** Significant LBM decrease after bed rest (-2.05 ± 0.66 kg; p = 0.02)
- **HMB group:** No significant LBM decrease after bed rest (-0.17 ± 0.19 kg; p = 0.23)
- **Between-group difference:** Significant (p = 0.02, ANOVA)
- **Female sub-analysis:** Significant difference in LBM change between groups (p = 0.04)
- No differences in function parameters observed (likely due to small sample size)

Conclusion:: In healthy older adults, HMB supplementation preserves muscle mass during 10 days of bed rest. These results need to be confirmed in a larger trial. Limitations:: Small sample size; healthy older adults not chronically ill; short bed rest duration (10 days) vs. ME/CFS chronicity; no PEM or fatigue assessment; HMB safety profile in ME/CFS unknown. ME/CFS Relevance:: Directly addresses muscle mass preservation during complete bed rest in older adults—a population with some parallels to severe ME/CFS. HMB is a leucine metabolite with anti-catabolic properties. The protocol (oral supplementation) is minimally invasive and suitable for bedbound patients. No active exercise required. PEM risk: LOW (nutritional intervention; does not increase physical or cognitive load). Certainty Assessment::

- *Quality:* Medium-High (Clinical Nutrition; RCT; double-blind; peer-reviewed)
- *Certainty:* 0.60
- *Limitation:* Healthy older adults; short bed rest; no PEM assessment

5 Standley et al. 2017 — HMB Effects on Mitochondria During Bed Rest

Full Citation:: Standley RA, Distefano G, Pereira SL, Tian M, Kelly OJ, Coen PM, Deutz NEP, Wolfe RR, Goodpaster BH. Effects of {\({\beta}\)}-hydroxy-{\({\beta}\)}-methylbutyrate on skeletal muscle mitochondrial content and dynamics, and lipids after 10 days of bed rest in older adults. Journal of Applied Physiology. 2017;123(5):1092–1100. (Standley et al. 2017) DOI:: 10.1152/japplphysiol.00192.2017 PMID:: 28705993 Published:: November 1, 2017 Study Design:: Randomized Controlled Trial Sample Size:: n=19 (60-76 yr), HMB=11, Control=8 Key Findings::

- Same cohort as Deutz 2013 (10 days bed rest + 8 weeks rehab)
- HMB: 3 g/day
- **Mitochondrial content and dynamics:**
  - No change in OXPHOS or mitochondrial dynamics after 10 days bed rest in either group
  - HMB maintained higher OXPHOS complex II protein after 8-week rehab (p < 0.05)
  - HMB maintained higher levels of DRP1 (fission) and MFN2 (fusion) after rehab (p < 0.05)
- **Autophagy and atrophy markers:**
  - Poly-ubiquitinated proteins increased after bed rest in both groups (main effect for time, p < 0.05)
  - BNIP3 and poly-ub proteins decreased after rehab in both groups (p < 0.05)
- **Lipids:**
  - Muscle triglyceride content tended to increase after bed rest in HMB group (p = 0.055)

Conclusion:: HMB influences mitochondrial dynamics and lipid metabolism during disuse atrophy and rehabilitation; maintains mitochondrial OXPHOS content and dynamics during rehabilitation. Limitations:: Small sample size; healthy older adults; short bed rest period; resistance training rehab not translatable; no assessment of symptom exacerbation or fatigue. ME/CFS Relevance:: Provides mechanistic data supporting HMB’s effects on mitochondrial health during disuse—directly relevant to ME/CFS mitochondrial dysfunction hypotheses. The maintenance of mitochondrial dynamics (fission/fusion balance) during rehabilitation suggests HMB may support mitochondrial recovery after periods of reduced activity. PEM risk: LOW (same as Deutz 2013; nutritional intervention). Certainty Assessment::

- *Quality:* Medium-High (Journal of Applied Physiology; RCT; mechanistic data)
- *Certainty:* 0.58
- *Limitation:* Healthy older adults; rehab not translatable; no PEM assessment

6 Dirks et al. 2015 — NMES Prevents Muscle Wasting in Comatose ICU Patients

Full Citation:: Dirks ML, Hansen D, Van Assche A, Dendale P, Van Loon LJ. Neuromuscular electrical stimulation prevents muscle wasting in critically ill comatose patients. Clinical Science. 2015;128(6):357–365. (Dirks et al. 2015) DOI:: 10.1042/CS20140447 PMID:: 25296344 Published:: March 2015 Study Design:: Clinical trial (within-subject crossover) Sample Size:: n=6 fully sedated ICU patients (3 males, 3 females) Key Findings::

- **Population:** Fully sedated ICU patients, age 63 ± 6 y, APACHE II: 29 ± 2 (high severity)
- **Protocol:** One leg received twice-daily NMES of quadriceps for 7 ± 1 days; other leg as non-stimulated control
- **Muscle fiber CSA:**
  - **Control leg:** Type I fibers decreased 16 ± 9% (p < 0.05); Type II fibers decreased 24 ± 7% (p < 0.05)
  - **Stimulated leg:** **No muscle atrophy observed**
- **mTOR pathway:** NMES increased mTOR phosphorylation by 19 ± 5% vs. baseline (p < 0.05); no change in control leg
- **Atrophy genes:** mRNA expression of FOXO1 declined (p < 0.05); MAFBx and MuRF1 unchanged; no differences between legs

Conclusion:: NMES represents an effective and feasible interventional strategy to prevent skeletal muscle atrophy in critically ill comatose patients. Limitations:: Very small sample size (n=6); short intervention period (7 days); ICU population with different pathophysiology; high severity of illness (APACHE II 29); no assessment of functional outcomes; no long-term follow-up. ME/CFS Relevance:: Directly addresses muscle atrophy prevention in fully sedated, immobilized patients—the closest physiological analog to severe/bedbound ME/CFS in the ICU literature. The within-subject design controls for individual variation. Mechanistic data (mTOR activation, atrophy gene suppression) provides biological plausibility. NMES is fully passive (requires no patient effort). PEM risk: LOW-MODERATE. NMES bypasses volitional activation and central fatigue, but may still trigger autonomic or metabolic responses. Certainty Assessment::

- *Quality:* Medium (Clinical Science; within-subject design; mechanistic data)
- *Certainty:* 0.50
- *Limitation:* Very small sample; short duration; no PEM assessment

7 Tiedemann2024 — UHRF1 Ubiquitin Ligase Supports Low-Density CpG Maintenance

Full Citation:: Tiedemann RL, Hrit J, Du Q, Wiseman AK, Kong NR, Eames H, Dickson BM, Rothbart SB. UHRF1 ubiquitin ligase activity supports the maintenance of low-density CpG methylation. Nucleic Acids Research. 2024;52(22):13733-13751. DOI:: 10.1093/nar/gkae1125 PMID:: 39607687 Key Findings::

- DNA methylation maintenance at low-density CpG regions is particularly vulnerable to disruption of UHRF1 ubiquitin ligase activity and DNMT1 ubiquitin reading activity.
- Low-CpG-density regions require UHRF1 ubiquitin ligase activity more than high-density regions for stable maintenance.
- Provides direct experimental support for a methylation density threshold below which maintenance fidelity degrades.

Conclusion:: The UHRF1-DNMT1 ubiquitin axis is the main protection mechanism for low-density CpG methylation. Disruption creates differential vulnerability based on local CpG density. Relevance:: Direct experimental support for the irreversibility threshold \(m_i^\text{crit}\) in the methylation vector model (Chapter Formal Causal Hierarchy Analysis, Per-Locus Dynamics: Vector Model for Bidirectional Methylation). Validates the concept that loci with sparse CpG methylation are harder to maintain. Quality:: High (Nucleic Acids Research; peer-reviewed; mechanistic with biochemical validation) Certainty:: 0.70 Limitations:: Cancer cell lines (HCT116, RKO); may not generalize to all genomic contexts. Single study; independent replication pending.

8 Crider2012 — Folate and DNA Methylation Review

Full Citation:: Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate’s Role. Advances in Nutrition. 2012;3(1):21-38. DOI:: 10.3945/an.111.000992 PMID:: 22332098 Key Findings::

- Folate, choline, betaine, vitamin B12, and other B vitamins serve as methyl donors and co-factors in one-carbon metabolism.
- SAM (S-adenosylmethionine) is the universal methyl donor for DNA methyltransferases.
- Three clinical trials examined impact of folic acid supplementation (0.4--10 mg/d) on global DNA methylation — results were mixed and context-dependent.
- Methyl-donor supplementation can affect DNA methylation levels but effect sizes are modest and depend on baseline methylation and genetic background.

Conclusion:: Methyl-donor supplementation has a plausible mechanistic basis for affecting DNA methylation but efficacy is not uniform. Baseline methylation status, genetic polymorphisms (MTHFR), and tissue type moderate response. Relevance:: General-population evidence cited to support methyl-donor support as the safe default strategy in the methylation vector model (Chapter Causal Hierarchy: Root Causes, Amplifiers, and Consequences, Speculation Consolidation as Loss of Methylation). No ME/CFS-specific data. Quality:: Medium-High (well-cited review summarizing multiple clinical trials) Certainty:: 0.60 Limitations:: Review paper, not a meta-analysis. Trials summarized are heterogeneous (different populations, doses, outcomes). No ME/CFS data.

9 Kok2015 — Long-Term Folic Acid and B12 Supplementation and DNA Methylation

Full Citation:: Kok DEG, Dhonukshe-Rutten RAM, Lute C, Heil SG, Uitterlinden AG, van der Velde N, et al. The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects. Clinical Epigenetics. 2015;7:113. DOI:: 10.1186/s13148-015-0154-5 PMID:: 26500703 Key Findings::

- Randomized controlled trial (n=87) of folic acid (400 mcg/day) + vitamin B12 (500 mcg/day) vs placebo for 2 years in elderly subjects.
- Genome-wide methylation profiling (Illumina 450K array) identified differentially methylated positions.
- Effect sizes were modest; methylation changes primarily in genes related to development and cellular processes.

Conclusion:: Long-term methyl-donor supplementation at moderate doses can produce measurable changes in DNA methylation profiles in humans. Effects are locus-specific and modest in magnitude. Relevance:: Demonstrates that methyl-donor supplementation is capable of modifying the methylation vector \(\mathbf{\mathcal{M}}\) in vivo — the premise underlying methyl-donor support as therapeutic strategy. General-population evidence; no ME/CFS data. Quality:: High (RCT design; peer-reviewed; genome-wide methylation measurement) Certainty:: 0.65 Limitations:: Elderly population (not ME/CFS); small sample size (n=87); 450K array limited CpG coverage; did not specifically assess repetitive element methylation.

10 Kimura2012 — DNMT1 Regulatory Mechanisms Review (Allosteric Switch)

Full Citation:: Kimura M, Sasaki H. An insight into the various regulatory mechanisms modulating human DNA methyltransferase 1 stability and function. Epigenetics. 2012;7(7):686-696. DOI:: 10.4161/epi.20157 PMID:: 22647247 Key Findings::

- DNMT1 operates via an allosteric binary switch — processive on highly methylated DNA, inactivated on poorly methylated/unmethylated sites.
- MeCP2 interacts directly with DNMT1 via the TRD domain, recruiting DNMT1 to methylated regions.
- UHRF1 recognizes hemimethylated CpGs and guides DNMT1; PCNA binding enhances processivity ~2-fold.
- This biphasic behavior creates stable methylation maintenance at high-density regions while preserving unmethylated regions — density-dependent maintenance fidelity.

Conclusion:: DNMT1 maintenance fidelity is not uniform across the genome. Methylation density determines maintenance robustness, with low-density CpG regions at higher risk of maintenance failure. Relevance:: Provides mechanistic foundation for the irreversibility threshold in the methylation vector model. Quality:: Medium-High (well-established review summarizing multiple mechanistic studies) Certainty:: 0.65 Limitations:: Review paper; mechanisms described at protein biochemistry level but critical threshold values for specific loci not quantified. No genome-wide locus-level resolution of density thresholds.

11 Strom2017 — Phase Separation Drives Heterochromatin Domain Formation

Full Citation:: Strom AR, Emelyanov AV, Mir M, Fyodorov DV, Darzacq X, Karpen GH. Phase separation drives heterochromatin domain formation. Nature. 2017;547:241-245. DOI:: 10.1038/nature22989 Key Findings::

- HP1a protein undergoes liquid-liquid phase separation (demixing) in vitro and nucleates into foci with liquid properties during early heterochromatin domain formation in Drosophila embryos.
- Heterochromatin domains exhibit dynamics characteristic of phase separation: sensitivity to hydrophobic disruption (1,6-hexanediol), reduced probe diffusion, increased coordinated movement, and inert probe exclusion at domain boundaries.
- Mature heterochromatin domains are not pure liquid — they solidify into stable compartments while retaining some liquid properties.
- Phase separation provides a nucleation threshold model: below a critical HP1 concentration/density, droplets cannot nucleate.

Conclusion:: Heterochromatin domains form via liquid-liquid phase separation driven by HP1a, maturing into structures with both liquid and solid properties. Domain formation requires a nucleation threshold. Relevance:: Supports the sigmoidal functional form for B-strength in the methylation vector model (Chapter Formal Causal Hierarchy Analysis). Below a critical HP1/H3K9me3 density at ProB repeats, liquid domain nucleation fails → compartment identity lost → genome unfolds. The phase-separation mechanism provides biophysical plausibility for a nonlinear (threshold) relationship between ProB methylation and B compartment integrity. Quality:: Very High (Nature; two-lab independent validation; Drosophila + mammalian cells; companion to Larson 2017) Certainty:: 0.75 Limitations:: Drosophila embryonic system and cultured cells; threshold values not quantified for specific genomic loci. Does not directly measure A/B compartment transitions in human cells.

12 Larson2017 — HP1α Liquid Droplet Formation and Phase Separation

Full Citation:: Larson AG, Elnatan D, Keenen MM, Trnka MJ, Johnston JB, Burlingame AL, Agard DA, Redding S, Narlikar GJ. Liquid droplet formation by HP1α suggests a role for phase separation in heterochromatin. Nature. 2017;547:236-240. DOI:: 10.1038/nature22822 Key Findings::

- Human HP1α protein forms phase-separated droplets in vitro; unmodified HP1α is soluble; phosphorylation or DNA binding promotes droplet formation.
- HP1α phase separation is reversible — specific ligands can dissolve droplets.
- Nucleosomes and DNA preferentially partition into HP1α droplets; transcription factors do not.
- HP1α phase-separation mutant (W200A) forms fewer and smaller nuclear puncta in mammalian cells — direct functional confirmation.
- Establishes concentration-dependent nucleation: below a critical HP1α concentration, no droplets form.

Conclusion:: Phase separation is an intrinsic biophysical property of HP1α protein, suggestible for heterochromatin assembly and gene silencing through physical sequestration of chromatin. Relevance:: Independent confirmation (different lab, human protein) that HP1-driven phase separation requires a concentration threshold. Supports the B-strength nucleation model — ProB repeat methylation loss reduces H3K9me3 → reduces HP1 binding → drops below nucleation threshold → heterochromatin domain dissolves. Companion to Strom 2017. Quality:: Very High (Nature; independent lab from Strom 2017; human protein; in vitro + cell-based validation) Certainty:: 0.75 Limitations:: In vitro biochemistry and cultured cells; does not directly measure compartment transitions in tissue. HP1α phase separation at endogenous expression levels not verified.

13 Mancini2026CPET — Null Replication of 2-Day CPET in ME/CFS

Full Citation:: Mancini DM, Cook DB, Brunjes DL, Soto T, Blate M, Quan P, Yamazaki T, Norweg A, Natelson BH. Cardiopulmonary exercise test results do not change over two sequential days in patients with chronic fatigue syndrome. Frontiers in Physiology. 2026;17:1816082. DOI:: 10.3389/fphys.2026.1816082 Key Findings::

- No significant Day 1→Day 2 change in peak VO₂ or VO₂ at VT in 58 ME/CFS (Fukuda criteria + PEM requirement) vs 25 sedentary controls
- ME/CFS had significantly higher Borg RPE at all workloads (p < 0.001)
- Lower maximal HR in ME/CFS (chronotropic incompetence in 9/58 vs 1/25 controls)
- 13/58 ME/CFS (22%) had ≥1 mL/kg/min VO₂ decline on Day 2 vs 8/25 controls (33%) — NS

Conclusion:: The data do not support using the 2-day CPET protocol to define PEM or disability. Changes in peak VO₂ or VO₂ at VT on 2-day CPET do not appear to be a good marker for PEM; subjective symptom monitoring post-exercise may be more sensitive. Quality:: Medium (peer-reviewed, decent n, controlled; Fukuda criteria less selective than CCC; single study; control group small at n=25) Certainty:: 0.60 Limitations:: Fukuda criteria (broader than CCC used in Keller 2024); single study not yet independently replicated; max-effort enforcement excludes patients who fail ACSM criteria on Day 2, which Keller argued is part of the PEM phenotype; abstract-only at time of initial discussion.

14 He2021 — eMSN in Primate Striatum

Full Citation:: He J, Kleyman M, Chen J, et al. Transcriptional and Anatomical Diversity of Medium Spiny Neurons in the Primate Striatum. Current Biology. 2021;31(24):5473-5486. DOI:: 10.1016/j.cub.2021.10.015 Key Findings::

- Identified nine distinct MSN subtypes in rhesus macaque striatum
- Confirmed D1/D2 hybrid neurons (eMSN) in primate striatum
- eMSN marker gene: RXFP1 (highly specific)
- eMSN express both DRD1 and DRD2 dopamine receptors
- eMSN constitute ~10% of MSNs in dorsal striatum
- Uniformly distributed throughout dorsal striatum
- Express high DRD1, low DRD2 compared to D2-MSNs

Conclusion:: eMSN are distinct MSN subtype with hybrid D1/D2 receptor expression, potentially integrating both direct and indirect basal ganglia pathways. Relevance:: Primary source for eMSN discovery and characterization in primates. Provides marker genes (RXFP1) for eMSN identification. Critical for eMSN biology but does not address ME/CFS. Quality:: High (peer-reviewed, Current Biology, rigorous methodology, FISH validation) Certainty:: 0.85 Limitations:: Primate model, not human; small N for tissue validation (n=2 for FISH); does not address ME/CFS or disease associations.

15 Siletti2023 — Human Brain Cell Atlas

Full Citation:: Siletti K, Hodge RD, Mossi Albiach A, et al. Transcriptomic diversity of cell types across the adult human brain. Science. 2023;382(6667). DOI:: 10.1126/science.add7046 Key Findings::

- Comprehensive single-nucleus RNA-seq atlas of entire human brain (3.3 million cells, 105 dissections)
- Identified 31 superclusters, 461 clusters, 3,313 subclusters
- High neuronal diversity outside cortex (hypothalamus, midbrain, hindbrain)
- eMSN confirmed in human brain: GAD1/GAD2 (CXCL14+ DRD1+ ADARB2+)
- Dataset publicly available for validation

Conclusion:: Unprecedented resolution of human brain cell types confirms eMSN as distinct cell type. Relevance:: Confirms eMSN presence in human brain and provides human-specific marker genes for identification. Establishes eMSN as validated human cell type. Essential reference for human eMSN biology but does not address ME/CFS. Quality:: Very High (landmark study, Science journal, peer-reviewed) Certainty:: 0.95 Limitations:: Postmortem tissue quality; limited donors (n=3); does not address ME/CFS or disease associations.

16 DecodeME2025 — ME/CFS GWAS (Brain Tissue Enrichment, No eMSN)

Full Citation:: DecodeME Genetics Consortium, Bretherick AD, Boutin T, Dibble JJ, et al. Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome. medRxiv. 2025. DOI:: 10.1101/2025.08.06.25333109 Key Findings::

- Largest ME/CFS GWAS: 15,579 cases vs 259,909 controls
- 8 genome-wide significant loci identified
- MAGMA analysis showed brain tissue enrichment in all 13 brain tissues
- Genes implicated in immune function (BTN2A2, OLFM4, RABGAP1L) and neurological processes (CA10, ARFGEF2)
- NO eMSN-specific findings reported (analysis was tissue-level, not cell-type specific)

Conclusion:: ME/CFS has genetic component with both immunological and neurological involvement. Brain tissue enrichment suggests striatal/basal ganglia relevance but eMSN not identified. Relevance:: First large-scale genetic evidence for ME/CFS. Brain tissue enrichment is significant but broad. Critical null result: no eMSN-specific genes despite brain enrichment (tissue-level analysis, not cell-type specific). Not a refutation of eMSN hypothesis but indicates cell-type specific analysis required. Quality:: High (large sample, rigorous methods, preprint) Certainty:: 0.80 Limitations:: Preprint (not peer-reviewed); limited to European ancestry; case definition challenges; no cell-type specific analysis.

17 Maccallini2025 — ME/CFS Disease Module (Metabolic Focus)

Full Citation:: Maccallini P. Toward a Disease Module for ME/CFS: A Network-Based Gene Prioritization. medRxiv. 2025. DOI:: 10.1101/2025.04.13.25325733 Key Findings::

- Network analysis of 22 seed genes from ME/CFS literature
- 272-gene ME/CFS module identified via STRING PPI + Random Walk with Restart
- Module enriched in: sphingolipid metabolism, energy-related pathways (oxidative phosphorylation, TP53-regulated genes), heme degradation, thermogenesis
- Overlap with neurodegenerative diseases (Parkinson's, Alzheimer's)
- NO eMSN or striatum-specific findings

Conclusion:: ME/CFS as metabolic network disorder with candidate genes for therapeutic targeting. Relevance:: Proposes ME/CFS disease module focusing on metabolic dysfunction. Does not support or refute eMSN hypothesis (different focus). Complementary to DecodeME: both find no eMSN but via different methods. Quality:: Medium (computational analysis, single author, preprint) Certainty:: 0.60 Limitations:: Preprint (not peer-reviewed); computational analysis only, no experimental validation; pseudogene substitution may introduce error; no cell-type specific analysis.

18 HealthRising2025 — ME/CFS Autopsy (CRH Depletion)

Full Citation:: Health Rising. ME/CFS Autopsy Study Finds a Wrecked HPA Axis: The 2025 IACFS Conference. 2025. URL:: https://www.healthrising.org/blog/2025/12/04/chronic-fatigue-hpa-axis-autopsy/ Key Findings::

- University of Amsterdam autopsy study of 7-10 ME/CFS patients
- Very low levels of CRH-producing neurons in hypothalamus
- Dramatic CRH depletion indicates HPA axis dysfunction
- No mention of striatum, eMSN, or basal ganglia findings

Conclusion:: Preliminary evidence for hypothalamic CRH depletion in ME/CFS supporting HPA axis dysfunction. Relevance:: Provides preliminary evidence for HPA axis dysfunction via CRH depletion. Critical: study focused on hypothalamus, not striatum; does not address eMSN. CRH is present in striatum but eMSN-specific CRH production unknown. Quality:: Low (secondary source, conference presentation, not peer-reviewed) Certainty:: 0.30 Limitations:: Secondary source (Health Rising blog); conference presentation not peer-reviewed; limited details; no primary publication yet; small sample size (n=7-10); no striatal analysis.

19 Da Silva 2025 — Hypothalamic CRH Neuron Depletion in ME/CFS (Conference)

Full Citation:: Da Silva JP. Hypothalamic CRH neuron depletion in severe ME/CFS: autopsy findings from the Netherlands Brain Bank ME/CFS donation programme. Conference presentation at IACFS/ME 2025. Not peer-reviewed. (Da Silva 2025) URL:: Health Rising summary (secondary source) Published:: 2025 (conference presentation — no preprint or primary publication as of July 2026) Study Design:: Post-mortem case-control immunocytochemistry; n=7 severe/very severe ME/CFS vs. matched controls Key Findings:

- Dramatically reduced CRH-producing neurons in the paraventricular nucleus of the hypothalamus
- Some cases showed near-absent CRH neurons
- Other hypothalamic neuron types (vasopressin/AVP, oxytocin/OXT) normal or increased — cell-type specific
- Downstream pituitary: regulatory hormone receptors downregulated; POMC/ACTH precursor reduced
- Picture: collapsed central stress/energy regulation

Interpretation:: Locates origin of ME/CFS hypocortisolism centrally (hypothalamus/pituitary), not adrenally. Proposed driver: chronic neuroinflammation → years-long CRH neuron overactivation → cell death. Cross-reference to Long COVID (RECOVER brain bank). Limitations:: Conference only, not peer-reviewed; n=7; single centre; no primary publication; no independent replication; end-stage only (cause vs. consequence); neuroinflammation not assessed in same brains. Quality:: Low (conference presentation, secondary source) Certainty:: 0.30

20 Raadsheer et al. 1994 — Increased CRH Neurons in Depression

Full Citation:: Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994;60(4):436–444. (Raadsheer et al. 1994) DOI:: 10.1159/000126778 Published:: 1994 Study Design:: Post-mortem immunocytochemistry + morphometry; Netherlands Brain Bank tissue Key Findings:

- CRH-expressing neuron number INCREASED in depression (opposite direction from ME/CFS finding)
- Same tissue source (NBB), same region (PVN), same cell-type quantification approach

Significance:: Provides methodology precedent for Da Silva 2025. The opposite CRH direction in depression vs ME/CFS suggests distinct pathophysiology — not simply “stress system burnout”. Quality:: High (peer-reviewed, established methodology, NBB tissue) Certainty:: 0.80

21 Meynen et al. 2007 — CRH Neuron Number in Alzheimer’s Depression

Full Citation:: Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJ. Relation between corticotropin-releasing hormone neuron number in the hypothalamic paraventricular nucleus and depressive state in Alzheimer’s disease. Neuroendocrinology. 2007;85(1):37–44. (Meynen et al. 2007) DOI:: 10.1159/000100582 Key Findings:: CRH neuron number in PVN related to depressive state in Alzheimer’s. Demonstrates Swaab group’s sustained methodology for PVN CRH quantification. Quality:: High (peer-reviewed) Certainty:: 0.75

22 Purba et al. 1995 — Increased CRH Neurons in Multiple Sclerosis

Full Citation:: Purba JS, Raadsheer FC, Hofman MA, Ravid R, Polman CH, Kamphorst W, Swaab DF. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinology. 1995;62(1):62–70. (Purba et al. 1995) DOI:: 10.1159/000126989 Key Findings:: PVN CRH neurons increased in MS (chronic neuroinflammatory condition). Opposite direction from ME/CFS depletion, showing CRH neurons respond differently to neuroinflammation across conditions. Quality:: High (peer-reviewed) Certainty:: 0.70

23 Morris et al. 2017 — HPA Hypofunction as Consequence of Immune-Inflammatory Pathways

Full Citation:: Morris G, Anderson G, Maes M. Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways. Molecular Neurobiology. 2017;54(9):6806–6819. (G. Morris, Anderson, and Maes 2017) DOI:: 10.1007/s12035-016-0170-2 Key Findings:: Argues HPA hypofunction in ME/CFS is secondary to immune-inflammatory and O&NS pathway activation. Provides mechanistic framework consistent with Da Silva’s neuroinflammatory driver model. Quality:: Medium-High (peer-reviewed, but hypothesis paper) Certainty:: 0.55

24 Tak et al. 2011 — HPA Axis Meta-Analysis in Functional Somatic Disorders

Full Citation:: Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, Rosmalen JG. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biological Psychology. 2011;87(2):183–194. (Tak et al. 2011) DOI:: 10.1016/j.biopsycho.2011.02.002 Key Findings:: Meta-analysis showing consistent hypocortisolism in CFS (moderate effect size), not attributable to comorbid depression or medication. Quality:: High (meta-analysis, peer-reviewed) Certainty:: 0.72

25 De Bellis et al. 2021 — Hypothalamic-Pituitary Autoimmunity in CFS

Full Citation:: De Bellis A, Bellastella G, Pernice V, Cirillo P, Longo M, Maiorino MI, Esposito K, Bellastella A. Hypothalamic-pituitary autoimmunity and related impairment of hormone secretions in chronic fatigue syndrome. Journal of Clinical Endocrinology and Metabolism. 2021;106(12):e5147–e5155. (De Bellis et al. 2021) DOI:: 10.1210/clinem/dgab429 Key Findings:: Anti-pituitary and anti-hypothalamus autoantibodies in CFS with associated hormone deficiencies. Presents competing autoimmune (not neurodegenerative) mechanism for central HPA failure. Conclusion:: Alternative mechanism: autoantibody-mediated pituitary/hypothalamic dysfunction rather than CRH neuron death. Quality:: Medium-High (peer-reviewed, JCEM) Certainty:: 0.55

26 Sauve et al. 2023 — GnRH Neuron Death in Long COVID Hypothalamus

Full Citation:: Sauve F, Nampoothiri S, Clarke SA, Fernandois D, Coelho CFF, et al. Long-COVID cognitive impairments and reproductive hormone deficits in men may stem from GnRH neuronal death. EBioMedicine. 2023;96:104784. (Sauve et al. 2023) DOI:: 10.1016/j.ebiom.2023.104784 Key Findings:: Post-mortem study demonstrating GnRH neuronal death in hypothalamus of male Long COVID patients. Establishes precedent for viral-induced hypothalamic neuron subtype loss. Same brain bank methodology (Netherlands Brain Bank / Erasmus MC). Conclusion:: Infection/inflammation → specific hypothalamic neuron subtype loss — mechanism directly maps to Da Silva’s CRH finding. Quality:: High (EBioMedicine, peer-reviewed, post-mortem) Certainty:: 0.65

27 Ferrero et al. 2017 — CNS Findings in CFS Autopsy

Full Citation:: Ferrero K, Silver M, Cocchetto A, Masliah E, Langford D. CNS findings in chronic fatigue syndrome and a neuropathological case report. Journal of Investigative Medicine. 2017;65(5):974–983. (Ferrero et al. 2017) DOI:: 10.1136/jim-2016-000390 Key Findings:: Case report + review of CFS neuropathology: gliosis, white matter changes. One of very few peer-reviewed autopsy studies in ME/CFS. No hypothalamic-specific analysis. Quality:: Medium (single case report + review) Certainty:: 0.40

References

Bao, W., J. Yang, M. Li, K. Chen, Z. Ma, Y. Bai, and Y. Xu. 2022. “Prevention of Muscle Atrophy in ICU Patients Without Nerve Injury by Neuromuscular Electrical Stimulation: A Randomized Controlled Study.” BMC Musculoskeletal Disorders 23 (1): 780. https://doi.org/10.1186/s12891-022-05739-2.

Da Silva, José Philipe. 2025. “Hypothalamic CRH Neuron Depletion in Severe ME/CFS: Autopsy Findings from the Netherlands Brain Bank ME/CFS Donation Programme.” Conference presentation at IACFS/ME 2025 (not peer-reviewed; reported via Health Rising blog). https://www.healthrising.org/blog/2025/12/04/chronic-fatigue-hpa-axis-autopsy/.

De Bellis, A., G. Bellastella, V. Pernice, P. Cirillo, M. Longo, M. I. Maiorino, K. Esposito, and A. Bellastella. 2021. “Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome.” Journal of Clinical Endocrinology and Metabolism 106 (12): e5147–55. https://doi.org/10.1210/clinem/dgab429.

Deutz, N. E. P., S. L. Pereira, N. P. Hays, J. S. Oliver, N. K. Edens, C. M. Evans, and R. R. Wolfe. 2013. “Effect of \({\beta}\)-Hydroxy-\({\beta}\)-Methylbutyrate (HMB) on Lean Body Mass During 10 Days of Bed Rest in Older Adults.” Clinical Nutrition 32 (5): 704–12. https://doi.org/10.1016/j.clnu.2013.02.011.

Dirks, M. L., D. Hansen, A. Van Assche, P. Dendale, and L. J. C. Van Loon. 2015. “Neuromuscular Electrical Stimulation Prevents Muscle Wasting in Critically Ill Comatose Patients.” Clinical Science 128 (6): 357–65. https://doi.org/10.1042/CS20140447.

Ferrero, K., M. Silver, A. Cocchetto, E. Masliah, and D. Langford. 2017. “CNS Findings in Chronic Fatigue Syndrome and a Neuropathological Case Report.” Journal of Investigative Medicine 65 (5): 974–83. https://doi.org/10.1136/jim-2016-000390.

Meynen, G., U. A. Unmehopa, M. A. Hofman, D. F. Swaab, and W. J. Hoogendijk. 2007. “Relation Between Corticotropin-Releasing Hormone Neuron Number in the Hypothalamic Paraventricular Nucleus and Depressive State in Alzheimer’s Disease.” Neuroendocrinology 85 (1): 37–44. https://doi.org/10.1159/000100582.

Morris, G., G. Anderson, and M. Maes. 2017. “Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways.” Molecular Neurobiology 54 (9): 6806–19. https://doi.org/10.1007/s12035-016-0170-2.

Morris, P. E., A. Goad, C. Thompson, K. Taylor, B. Harry, L. Passmore, A. Ross, et al. 2008. “Early Intensive Care Unit Mobility Therapy in the Treatment of Acute Respiratory Failure.” Critical Care Medicine 36 (8): 2238–43. https://doi.org/10.1097/CCM.0b013e318180b90e.

Purba, J. S., F. C. Raadsheer, M. A. Hofman, R. Ravid, C. H. Polman, W. Kamphorst, and D. F. Swaab. 1995. “Increased Number of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Patients with Multiple Sclerosis.” Neuroendocrinology 62 (1): 62–70. https://doi.org/10.1159/000126989.

Raadsheer, F. C., W. J. Hoogendijk, F. C. Stam, F. J. Tilders, and D. F. Swaab. 1994. “Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients.” Neuroendocrinology 60 (4): 436–44. https://doi.org/10.1159/000126778.

Sauve, F., S. Nampoothiri, S. A. Clarke, D. Fernandois, C. F. F. Coelho, J. Dewisme, E. G. Mills, et al. 2023. “Long-COVID Cognitive Impairments and Reproductive Hormone Deficits in Men May Stem from GnRH Neuronal Death.” EBioMedicine 96: 104784. https://doi.org/10.1016/j.ebiom.2023.104784.

Standley, R. A., G. Distefano, S. L. Pereira, M. Tian, O. J. Kelly, P. M. Coen, N. E. P. Deutz, R. R. Wolfe, and B. H. Goodpaster. 2017. “Effects of \({\beta}\)-Hydroxy-\({\beta}\)-Methylbutyrate on Skeletal Muscle Mitochondrial Content and Dynamics, and Lipids After 10 Days of Bed Rest in Older Adults.” Journal of Applied Physiology 123 (5): 1092–1100. https://doi.org/10.1152/japplphysiol.00192.2017.

Tak, L. M., A. J. Cleare, J. Ormel, A. Manoharan, I. C. Kok, S. Wessely, and J. G. Rosmalen. 2011. “Meta-Analysis and Meta-Regression of Hypothalamic-Pituitary-Adrenal Axis Activity in Functional Somatic Disorders.” Biological Psychology 87 (2): 183–94. https://doi.org/10.1016/j.biopsycho.2011.02.002.

Wollersheim, T., K. Haas, S. Wolf, K. Mai, C. Spies, E. Steinhagen-Thiessen, K. D. Wernecke, J. Spranger, and S. Weber-Carstens. 2017. “Whole-Body Vibration to Prevent Intensive Care Unit-Acquired Weakness: Safety, Feasibility, and Metabolic Response.” Critical Care 21 (1): 9. https://doi.org/10.1186/s13054-016-1576-y.